drugset / Trial / NCT03632291
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of UB-221 as an add-on therapy in patients with Chronic Spontaneous Urticaria.
Timeline
- Start
- 2019-04-09
- Primary completion
- 2021-01-19
- Completion
- 2021-01-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UB-221 | Monoclonal antibody | 0.2 mg/kg | Intravenous |
| Subject | UB-221 | Monoclonal antibody | 0.6 mg/kg | Intravenous |
| Subject | UB-221 | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | UB-221 | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | UB-221 | Monoclonal antibody | 10 mg/kg | Intravenous |